Five Prime Therapeutics Announces Option Exercise by GlaxoSmithKline For A Commercial License To A Novel Muscle Disease Target
September 15, 2014 at 16:06 PM EDT
Five Prime Therapeutics, Inc. (Nasdaq: FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing ...